# **Accepted Manuscript**

A Long-term Safety Study of Latanoprost in Pediatric Patients with Glaucoma and Ocular Hypertension: A Prospective Cohort Study

Muhammad Younus, Ronald A. Schachar, Min Zhang, Marla B. Sultan, Charles S. Tressler, Kui Huang, Wanning Xu, Mitchel Klein, Robert W. Platt, Nandita Mukherjee, Estelle Haenel, Sharon F. Freedman

PII: S0002-9394(18)30500-2

DOI: 10.1016/j.ajo.2018.08.039


Reference: AJOPHT 10657

To appear in: American Journal of Ophthalmology

Received Date: 16 February 2018
Revised Date: 28 August 2018
Accepted Date: 28 August 2018

Please cite this article as: Younus M, Schachar RA, Zhang M, Sultan MB, Tressler CS, Huang K, Xu W, Klein M, Platt RW, Mukherjee N, Haenel E, Freedman SF, A Long-term Safety Study of Latanoprost in Pediatric Patients with Glaucoma and Ocular Hypertension: A Prospective Cohort Study, *American Journal of Ophthalmology* (2018), doi: 10.1016/j.ajo.2018.039.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



#### ACCEPTED MANUSCRIPT

**Title:** A Long-term Safety Study of Latanoprost in Pediatric Patients with Glaucoma and Ocular Hypertension: A Prospective Cohort Study

Short title: Latanoprost Safety in pediatric glaucoma patients

**Authors:** Muhammad Younus, <sup>1</sup> Ronald A. Schachar, <sup>2</sup> Min Zhang, <sup>2</sup> Marla B. Sultan, <sup>3</sup> Charles S. Tressler, <sup>6</sup> Kui Huang, <sup>3</sup> Wanning Xu, <sup>3</sup> Mitchel Klein, <sup>4</sup> Robert W. Platt, <sup>5</sup> Nandita Mukherjee, <sup>6</sup> Estelle Haenel, <sup>2</sup> Sharon F. Freedman <sup>7</sup>

**Affiliations:** <sup>1</sup>Epidemiology, Worldwide Safety and Strategy, Pfizer Inc, New York, New York; <sup>2</sup> Pfizer Essential Heath, Pfizer Inc, New York, New York, New York; <sup>3</sup>Global Product Development, Pfizer Inc, New York, New York; <sup>4</sup>Environmental Health and Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia; <sup>5</sup>Departments of Pediatrics, and Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec; <sup>6</sup>Safety Surveillance and Risk Management, Worldwide Safety and Regulatory; Pfizer Inc, New York, New York; <sup>7</sup>Pediatric Ophthalmology and Strabismus Service, Duke Eye Center, Duke University School of Medicine, Durham, North Carolina

## **Corresponding Author:**

Muhammad Younus Epidemiology, Worldwide Safety and Regulatory, Pfizer Inc.

500 Arcola Road, Collegeville, PA 19426, USA Phone number: (484)865-6663

Fax number: (484)323-7851

E-mail: muhammad.younus2@pfizer.com

ClinicalTrials.Gov identifiers: NCT01265719

### Download English Version:

# https://daneshyari.com/en/article/11021976

Download Persian Version:

https://daneshyari.com/article/11021976

Daneshyari.com